C4 Therapeutics (CCCC) Accumulated Expenses (2019 - 2026)

C4 Therapeutics' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $9.8 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 22.19% year-over-year to $9.8 million; the TTM figure through Mar 2026 stood at $9.8 million (down 22.19% YoY), while the FY2025 annual figure was $13.3 million, down 31.24% from the prior year.
• Accumulated Expenses was $9.8 million for Q1 2026 at C4 Therapeutics, down from $13.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $20.6 million in Q4 2023 to a low of $6.7 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $14.7 million across 5 years, with a median of $15.4 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses soared 529.94% in 2022, then tumbled 33.03% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $19.8 million in 2022, then increased by 4.36% to $20.6 million in 2023, then declined by 6.14% to $19.4 million in 2024, then tumbled by 31.24% to $13.3 million in 2025, then dropped by 26.17% to $9.8 million in 2026.
• The last three Accumulated Expenses figures came in at $9.8 million (Q1 2026), $13.3 million (Q4 2025), and $11.3 million (Q3 2025), per Business Quant data.